HUP0000261A2 - Módszer prosztatatúltengés és prosztatarák kezelésére - Google Patents

Módszer prosztatatúltengés és prosztatarák kezelésére

Info

Publication number
HUP0000261A2
HUP0000261A2 HU0000261A HUP0000261A HUP0000261A2 HU P0000261 A2 HUP0000261 A2 HU P0000261A2 HU 0000261 A HU0000261 A HU 0000261A HU P0000261 A HUP0000261 A HU P0000261A HU P0000261 A2 HUP0000261 A2 HU P0000261A2
Authority
HU
Hungary
Prior art keywords
prostate
prostate cancer
hypertrophy
treating
cancer
Prior art date
Application number
HU0000261A
Other languages
English (en)
Inventor
Jürgen Engel
Jürgen Rawert
Thomas Reissmann
Hilde Riethmüller-Winzen
Original Assignee
Asta Medica Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asta Medica Aktiengesellschaft filed Critical Asta Medica Aktiengesellschaft
Publication of HUP0000261A2 publication Critical patent/HUP0000261A2/hu
Publication of HUP0000261A3 publication Critical patent/HUP0000261A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Abstract

A találmány tárgya gyógyszerkészítmény benignus prosztata hiperpláziaés prosztata rák emlős szervezetekben történő kezelésére, anélkül,hogy a tesztroszteronszint a kasztráltságra jellemző tartományba esne,mely készítmény az LHRH-antagonistát önmagában vagy a-reduktázinhibitorokkal vagy a-receptor blokkolókkal kombinációban tartalmazza. Ó
HU0000261A 1996-09-12 1997-09-01 Means for treating prostate hypertrophy and prostate cancer HUP0000261A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2599096P 1996-09-12 1996-09-12
US4322897P 1997-04-10 1997-04-10
PCT/EP1997/004740 WO1998010781A1 (en) 1996-09-12 1997-09-01 Means for treating prostate hypertrophy and prostate cancer

Publications (2)

Publication Number Publication Date
HUP0000261A2 true HUP0000261A2 (hu) 2000-10-28
HUP0000261A3 HUP0000261A3 (en) 2001-03-28

Family

ID=26700570

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0000261A HUP0000261A3 (en) 1996-09-12 1997-09-01 Means for treating prostate hypertrophy and prostate cancer

Country Status (29)

Country Link
US (4) US6054432A (hu)
EP (1) EP0925069B1 (hu)
JP (1) JP2001500500A (hu)
KR (1) KR100546235B1 (hu)
CN (1) CN1126566C (hu)
AR (1) AR009757A1 (hu)
AT (1) ATE370743T1 (hu)
AU (1) AU738306B2 (hu)
BR (1) BR9713197A (hu)
CA (1) CA2215015A1 (hu)
CZ (1) CZ298738B6 (hu)
DE (1) DE69738045T2 (hu)
DK (1) DK0925069T3 (hu)
EE (1) EE04000B1 (hu)
ES (1) ES2289764T3 (hu)
HK (1) HK1021937A1 (hu)
HU (1) HUP0000261A3 (hu)
IL (3) IL128331A0 (hu)
IS (1) IS4978A (hu)
MX (1) MXPA99002420A (hu)
NO (1) NO326207B1 (hu)
NZ (1) NZ334540A (hu)
PL (1) PL193184B1 (hu)
PT (1) PT925069E (hu)
RU (1) RU2215537C2 (hu)
SK (1) SK286174B6 (hu)
TR (1) TR199900556T2 (hu)
TW (1) TWI224002B (hu)
WO (1) WO1998010781A1 (hu)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6828415B2 (en) 1993-02-19 2004-12-07 Zentaris Gmbh Oligopeptide lyophilisate, their preparation and use
US6054432A (en) * 1996-09-12 2000-04-25 Asta Medica Aktiengesellschaft Means for treating prostate hypertrophy and prostate cancer
FR2768055A1 (fr) * 1997-09-11 1999-03-12 Synthelabo Utilisation de derives de sulfonanilide pour obtenir un medicament destine au traitement de l'ejaculation retrograde ou de l'aspermie
TW536402B (en) * 1998-06-26 2003-06-11 Yamanouchi Pharma Co Ltd Pharmaceutical composition for the therapy of voiding dysfunction
DE19911771B4 (de) * 1999-03-17 2006-03-30 Zentaris Gmbh LHRH-Antagonist, Verfahren zu seiner Herstellung und seiner Verwendung
US7105560B1 (en) 1999-07-23 2006-09-12 The Regents Of The University Of California Use of etodolac in the treatment of multiple myeloma
US7361680B2 (en) * 1999-07-23 2008-04-22 The Regents Of The University Of California Indole compounds useful for the treatment of cancer
US7151100B1 (en) * 1999-07-23 2006-12-19 The Regents Of The University Of California Indole compounds useful for the treatment of cancer
US6545034B1 (en) * 1999-07-23 2003-04-08 The Regents Of The University Of California Use of etodolac for the treatment of chronic lymphocytic leukemia
US7129262B2 (en) * 1999-07-23 2006-10-31 The Regents Of The University Of California Indole compounds useful for the treatment of cancer
ID30249A (id) * 1999-08-09 2001-11-15 Yamanouchi Pharma Co Ltd Komposisi farmasi untuk terapi gejala-gejala penyakit pelaksanaan fungsi saluran air kencing bawah
EP1955700B9 (en) 1999-09-30 2011-09-07 Harbor BioSciences, Inc. Therapeutic treatment of androgen receptor driven conditions
US20040152672A1 (en) * 2000-08-09 2004-08-05 Carson Dennis A. Indole compounds useful for the treatment of cancer
KR100876538B1 (ko) * 2000-08-17 2008-12-31 아에테르나 젠타리스 게엠베하 Ｌｈｒｈ 길항제의 염의 제조방법
DE10040700A1 (de) * 2000-08-17 2002-02-28 Asta Medica Ag Salze von biologisch aktiven Peptiden, ihre Herstellung und Verwendung
JP2001288115A (ja) * 2001-02-07 2001-10-16 Yamanouchi Pharmaceut Co Ltd 下部尿路症治療剤
DE10137174A1 (de) * 2001-07-31 2003-02-13 Zentaris Ag Verwendung von LHRH-Antagonisten in nichtkastrierenden Dosen zur Verbesserung der T-Zellen-vermittelten Immunität
WO2004026116A2 (en) * 2002-09-19 2004-04-01 The Regents Of The University Of California Use of etodoclac to treat hyperplasia
GB0301016D0 (en) * 2003-01-16 2003-02-19 Univ London Treatment of benign prostatic hyperplasia
MXPA05007572A (es) 2003-01-17 2005-11-17 Threshold Pharmaceuticals Inc Tratamiento de hiperplasia prostatica benigna.
AR060748A1 (es) * 2006-05-03 2008-07-10 Wisconsin Alumni Res Found Compuestos de n1, n4- bis ( buta-1,3- dienil) butano-1,4- diamina y metodos de tratamiento de los mismos
EP1891964A1 (en) * 2006-08-08 2008-02-27 AEterna Zentaris GmbH Application of initial doses of LHRH analogues and maintenance doses of LHRH antagonists for the treatment of hormone-dependent cancers and corresponding pharmaceutical kits
EP1967202A1 (en) * 2007-03-05 2008-09-10 AEterna Zentaris GmbH Use of LHRH Antagonists for the Treatment of Lower Urinary Tract Symptoms, in particular Overactive Bladder and/or Detrusor Overactivity
EP2095818A1 (en) * 2008-02-29 2009-09-02 AEterna Zentaris GmbH Use of LHRH antagonists at non-castrating doses
US10585101B2 (en) 2016-03-10 2020-03-10 Wavesense, Inc. Prostatic liquid biopsy for the detection of prostate cancer and benign prostatic hyperplasia

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU199694B (en) * 1988-05-10 1990-03-28 Innofinance Altalanos Innovaci Process for producing citostatic pharmaceutical compositions containing gonadoliberin derivatives
DE3918543A1 (de) * 1989-06-07 1990-12-13 Boehringer Mannheim Gmbh Verwendung von naftopidil zur therapie der dysurie bei benigner prostata-hypertrophie
IL101245A0 (en) * 1991-03-20 1992-11-15 Merck & Co Inc Pharmaceutical compositions for the treatment of prostatic cancer
US6054432A (en) * 1996-09-12 2000-04-25 Asta Medica Aktiengesellschaft Means for treating prostate hypertrophy and prostate cancer

Also Published As

Publication number Publication date
US5998377A (en) 1999-12-07
MXPA99002420A (es) 2004-08-27
IS4978A (is) 1999-02-16
NO991192L (no) 1999-04-28
IL128331A0 (en) 2000-01-31
WO1998010781A1 (en) 1998-03-19
TR199900556T2 (xx) 1999-07-21
TWI224002B (en) 2004-11-21
CZ298738B6 (cs) 2008-01-09
US6071882A (en) 2000-06-06
AU4619897A (en) 1998-04-02
AR009757A1 (es) 2000-05-03
CN1230121A (zh) 1999-09-29
CA2215015A1 (en) 1998-03-12
PL332085A1 (en) 1999-08-30
PL193184B1 (pl) 2007-01-31
DE69738045T2 (de) 2008-05-15
CN1126566C (zh) 2003-11-05
RU2215537C2 (ru) 2003-11-10
HUP0000261A3 (en) 2001-03-28
US6054432A (en) 2000-04-25
US6300313B1 (en) 2001-10-09
DE69738045D1 (de) 2007-10-04
IL189132A0 (en) 2008-06-05
SK30199A3 (en) 2000-03-13
DK0925069T3 (da) 2007-10-29
KR100546235B1 (ko) 2006-01-26
AU738306B2 (en) 2001-09-13
EP0925069A1 (en) 1999-06-30
EE04000B1 (et) 2003-04-15
ES2289764T3 (es) 2008-02-01
JP2001500500A (ja) 2001-01-16
KR20010029495A (ko) 2001-04-06
IL128331A (en) 2010-05-31
NO326207B1 (no) 2008-10-20
EP0925069B1 (en) 2007-08-22
NO991192D0 (no) 1999-03-11
EE9900121A (et) 1999-10-15
NZ334540A (en) 2000-07-28
PT925069E (pt) 2007-10-17
CZ80899A3 (cs) 1999-11-17
HK1021937A1 (en) 2000-07-21
BR9713197A (pt) 2000-04-04
ATE370743T1 (de) 2007-09-15
SK286174B6 (sk) 2008-04-07

Similar Documents

Publication Publication Date Title
HUP0000261A2 (hu) Módszer prosztatatúltengés és prosztatarák kezelésére
DE60023982D1 (de) System zur Behandlung von benigner Prostatahyperplasie
DK0968208T3 (da) Quinolin- og quinazolin-forbindelser som er nyttige i terapi især til behandling af godartet prostatisk hyperplasia
ATE208210T1 (de) Kombination von proteintyrosin-kinaseinhibitoren und chemischer kastration zur behandlung von prostatakrebs
DK1084569T3 (da) Androgener i kombination med gestagener til udligning af et testosteronunderskud med beskyttelse af prostata
PL350291A1 (en) Method of using a cyclooxygenase-2 inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
NO308037B1 (no) 16-substituerte-4-aza-androstan 5<alfa>-reduktase-isoenzym 1- inhibitorer og farmasøytisk preparat
ZA972600B (en) Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia
RS92304A (en) Pharmaceutical combination for the treatment of benign prostatic hyperplasia or for long-term preservation of acute urinary retention
ZA982819B (en) Treatment or prophylaxis of prostatic cancer and benign prostatic hyperplasia with selective estrogn receptor modulators.
TR199701613T1 (xx) Selim prostatik hiperplasyan�n tedavisi i�in melatonin agonistleri.
EP1435913A4 (en) METHOD OF TREATING BENIGN PROSTATIC HYPERPLASIA AND OTHER BENCH PROSTATIC PATHOLOGIES
SI0925069T1 (sl) Uporaba Cetrorelix-a za zdravljenje benigne hipertrofije prostate in prostatnega raka
GB9810895D0 (en) Combination therapy for the treatment of benign prostatic hyperplasia
SI1501517T1 (sl) Farmacevtska kombinacija za zdravljenje benigne hiperplazije prostate ali za dolgotrajno preprečevanje akutne retencije urina
MX9710075A (es) Antagonistas melatonina para el tratamiento en la hiperplasia prostatica benigna.

Legal Events

Date Code Title Description
HC9A Change of name, address

Owner name: ZENTARIS GMBH, DE

Free format text: FORMER OWNER(S): ASTA MEDICA AKTIENGESELLSCHAFT, DE; ZENTARIS AG, DE; ZENTARIS GMBH, DE

FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished